Symbols / QURE $17.39 +1.34% uniQure N.V.
QURE Chart
About
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.09B |
| Enterprise Value | 987.06M | Income | -198.97M | Sales | 16.10M |
| Book/sh | 3.19 | Cash/sh | 9.96 | Dividend Yield | — |
| Payout | 0.00% | Employees | 221 | IPO | — |
| P/E | — | Forward P/E | -6.44 | PEG | — |
| P/S | 67.55 | P/B | 5.45 | P/C | — |
| EV/EBITDA | -6.01 | EV/Sales | 61.31 | Quick Ratio | 9.99 |
| Current Ratio | 10.43 | Debt/Eq | 269.78 | LT Debt/Eq | — |
| EPS (ttm) | -3.46 | EPS next Y | -2.70 | EPS Growth | — |
| Revenue Growth | 6.60% | Earnings | 2026-05-07 | ROA | -16.21% |
| ROE | -207.10% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -9.01% | Profit Margin | 0.00% | Shs Outstand | 62.53M |
| Shs Float | 49.19M | Short Float | 20.58% | Short Ratio | 2.14 |
| Short Interest | — | 52W High | 71.50 | 52W Low | 7.76 |
| Beta | 0.75 | Avg Volume | 3.38M | Volume | 882.76K |
| Target Price | $37.80 | Recom | None | Prev Close | $17.16 |
| Price | $17.39 | Change | 1.34% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-23 | main | Barclays | Equal-Weight → Equal-Weight | $25 |
| 2026-03-11 | up | Mizuho | Neutral → Outperform | $35 |
| 2026-03-10 | reit | HC Wainwright & Co. | Buy → Buy | $70 |
| 2026-03-09 | main | Chardan Capital | Buy → Buy | $31 |
| 2026-03-09 | up | RBC Capital | Sector Perform → Outperform | $35 |
| 2026-03-09 | up | Wells Fargo | Equal-Weight → Overweight | $60 |
| 2026-03-03 | main | Goldman Sachs | Neutral → Neutral | $9 |
| 2026-03-03 | down | Wells Fargo | Overweight → Equal-Weight | $15 |
| 2026-03-03 | main | Chardan Capital | Buy → Buy | $16 |
| 2026-03-03 | down | Mizuho | Outperform → Neutral | $12 |
| 2026-03-02 | up | Cantor Fitzgerald | Overweight → Neutral | $9 |
| 2026-02-24 | init | Wolfe Research | — → Peer Perform | — |
| 2026-02-10 | reit | HC Wainwright & Co. | Buy → Buy | $70 |
| 2026-01-28 | init | Barclays | — → Equal-Weight | $31 |
| 2025-12-11 | main | Stifel | Buy → Buy | $40 |
| 2025-12-09 | main | Mizuho | Outperform → Outperform | $33 |
| 2025-12-04 | main | Chardan Capital | Buy → Buy | $53 |
| 2025-11-12 | main | Wells Fargo | Overweight → Overweight | $60 |
| 2025-11-11 | main | Chardan Capital | Buy → Buy | $53 |
| 2025-11-10 | main | Leerink Partners | Outperform → Outperform | $60 |
- uniQure (QURE) Faces FDA Rebuke, Lawsuits Over AMT-130 Disclosures Is Its Credibility at Risk? - simplywall.st Sun, 05 Apr 2026 20
- Levi & Korsinsky Reminds uniQure N.V. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 13, 2026 - QURE - PR Newswire Wed, 01 Apr 2026 13
- QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire hu, 02 Apr 2026 14
- QURE Stock Crashes 32% in a Week: Here's What You Should Know - Yahoo Finance Fri, 06 Mar 2026 08
- uniQure Stock: Worst Case Scenario Becomes Reality (NASDAQ:QURE) - Seeking Alpha ue, 03 Mar 2026 08
- uniQure Stock Surges 26% Following News That Key FDA official Will Step Down - TIKR.com ue, 10 Mar 2026 07
- INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming Deadlines - QURE - PR Newswire hu, 02 Apr 2026 14
- UNIQURE N.V. (QURE) SHAREHOLDER ALERT Bernstein Liebhard - GlobeNewswire hu, 02 Apr 2026 15
- Is Regulatory Scrutiny of AMT-130 Quietly Rewriting uniQure’s (QURE) Gene Therapy Investment Story? - ca.finance.yahoo.com Sun, 05 Apr 2026 02
- uniQure Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against uniQure N.V. - QURE - PR Newswire Sat, 04 Apr 2026 00
- A Look At uniQure (QURE) Valuation After Its Sharp Recent Share Price Rebound - simplywall.st Fri, 03 Apr 2026 02
- QURE SHAREHOLDER NOTICE: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of "Distorted" Data - PR Newswire Fri, 20 Mar 2026 20
- UNIQURE DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, - GlobeNewswire hu, 02 Apr 2026 22
- QURE Shareholder Alert: uniQure N.V. Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm - PR Newswire ue, 31 Mar 2026 13
- uniQure N.V. (QURE) Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP: Investors Face April 13, 2026, Deadline - PR Newswire Mon, 30 Mar 2026 17
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
16.10
-40.64%
|
27.12
+71.17%
|
15.84
-85.12%
|
106.48
|
| Operating Revenue |
|
16.10
-40.64%
|
27.12
+71.17%
|
15.84
-85.12%
|
106.48
|
| Cost Of Revenue |
|
1.69
-90.80%
|
18.33
+34.48%
|
13.63
+307.66%
|
3.34
|
| Reconciled Cost Of Revenue |
|
1.69
-78.37%
|
7.80
+106.30%
|
3.78
+13.04%
|
3.34
|
| Gross Profit |
|
14.41
+63.92%
|
8.79
+296.93%
|
2.21
-97.85%
|
103.14
|
| Operating Expense |
|
202.24
+5.90%
|
190.97
-32.92%
|
284.70
+15.08%
|
247.39
|
| Research And Development |
|
140.67
-2.16%
|
143.78
-33.08%
|
214.86
+8.74%
|
197.59
|
| Selling General And Administration |
|
65.34
+28.92%
|
50.68
-30.65%
|
73.08
+33.60%
|
54.70
|
| General And Administrative Expense |
|
65.34
+28.92%
|
50.68
-30.65%
|
73.08
+33.60%
|
54.70
|
| Salaries And Wages |
|
35.04
+5.32%
|
33.27
-20.38%
|
41.78
+14.34%
|
36.54
|
| Other Gand A |
|
28.50
+77.57%
|
16.05
-47.18%
|
30.39
+75.34%
|
17.33
|
| Other Operating Expenses |
|
-5.68
-1.41%
|
-5.60
-5.84%
|
-5.29
+13.00%
|
-6.08
|
| Total Expenses |
|
203.93
-2.57%
|
209.30
-29.84%
|
298.33
+18.98%
|
250.73
|
| Operating Income |
|
-187.83
-3.10%
|
-182.18
+35.51%
|
-282.49
-95.84%
|
-144.25
|
| Total Operating Income As Reported |
|
-185.35
-0.57%
|
-184.29
+34.85%
|
-282.87
-97.59%
|
-143.16
|
| EBITDA |
|
-116.59
+27.47%
|
-160.75
+36.49%
|
-253.10
-134.31%
|
-108.02
|
| Normalized EBITDA |
|
-148.72
+0.96%
|
-150.16
+40.00%
|
-250.26
-86.69%
|
-134.05
|
| Reconciled Depreciation |
|
14.76
+16.76%
|
12.64
+6.23%
|
11.90
+39.39%
|
8.54
|
| EBIT |
|
-131.35
+24.25%
|
-173.39
+34.57%
|
-265.00
-127.36%
|
-116.56
|
| Total Unusual Items |
|
32.13
+403.70%
|
-10.58
-272.27%
|
-2.84
-110.92%
|
26.04
|
| Total Unusual Items Excluding Goodwill |
|
32.13
+403.70%
|
-10.58
-272.27%
|
-2.84
-110.92%
|
26.04
|
| Special Income Charges |
|
6.00
+8319.18%
|
-0.07
+79.78%
|
-0.36
|
0.00
|
| Restructuring And Mergern Acquisition |
|
0.00
-100.00%
|
1.22
+238.78%
|
0.36
|
0.00
|
| Net Income |
|
-198.97
+16.94%
|
-239.56
+22.34%
|
-308.48
-143.30%
|
-126.79
|
| Pretax Income |
|
-193.34
+18.47%
|
-237.13
+22.65%
|
-306.56
-139.01%
|
-128.26
|
| Net Non Operating Interest Income Expense |
|
-45.03
-6.38%
|
-42.33
-92.43%
|
-22.00
-98.24%
|
-11.10
|
| Interest Expense Non Operating |
|
61.99
-2.74%
|
63.74
+53.38%
|
41.56
+255.07%
|
11.70
|
| Net Interest Income |
|
-45.03
-6.38%
|
-42.33
-92.43%
|
-22.00
-98.24%
|
-11.10
|
| Interest Expense |
|
61.99
-2.74%
|
63.74
+53.38%
|
41.56
+255.07%
|
11.70
|
| Interest Income Non Operating |
|
16.97
-20.77%
|
21.41
+9.47%
|
19.56
+3112.15%
|
0.61
|
| Interest Income |
|
16.97
-20.77%
|
21.41
+9.47%
|
19.56
+3112.15%
|
0.61
|
| Other Income Expense |
|
39.51
+413.08%
|
-12.62
-507.95%
|
-2.08
-107.65%
|
27.12
|
| Other Non Operating Income Expenses |
|
7.38
+461.73%
|
-2.04
-366.45%
|
0.77
-29.53%
|
1.09
|
| Gain On Sale Of Security |
|
26.13
+348.70%
|
-10.51
-323.50%
|
-2.48
-109.53%
|
26.04
|
| Gain On Sale Of Business |
|
0.00
-100.00%
|
1.15
|
0.00
|
0.00
|
| Tax Provision |
|
5.63
+131.82%
|
2.43
+26.44%
|
1.92
+230.68%
|
-1.47
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+2151.11%
|
0.00
|
| Tax Effect Of Unusual Items |
|
8.29
+403.70%
|
-2.73
-272.27%
|
-0.73
-345.73%
|
0.30
|
| Net Income Including Noncontrolling Interests |
|
-198.97
+16.94%
|
-239.56
+22.34%
|
-308.48
-143.30%
|
-126.79
|
| Net Income From Continuing Operation Net Minority Interest |
|
-198.97
+16.94%
|
-239.56
+22.34%
|
-308.48
-143.30%
|
-126.79
|
| Net Income From Continuing And Discontinued Operation |
|
-198.97
+16.94%
|
-239.56
+22.34%
|
-308.48
-143.30%
|
-126.79
|
| Net Income Continuous Operations |
|
-198.97
+16.94%
|
-239.56
+22.34%
|
-308.48
-143.30%
|
-126.79
|
| Normalized Income |
|
-222.81
+3.84%
|
-231.71
+24.37%
|
-306.37
-100.86%
|
-152.53
|
| Net Income Common Stockholders |
|
-198.97
+16.94%
|
-239.56
+22.34%
|
-308.48
-143.30%
|
-126.79
|
| Diluted EPS |
|
-3.46
+29.67%
|
-4.92
+23.96%
|
-6.47
-138.75%
|
-2.71
|
| Basic EPS |
|
-3.46
+29.67%
|
-4.92
+23.96%
|
-6.47
-138.75%
|
-2.71
|
| Basic Average Shares |
|
57.50
+18.20%
|
48.65
+2.05%
|
47.67
+2.00%
|
46.74
|
| Diluted Average Shares |
|
57.50
+18.20%
|
48.65
+2.05%
|
47.67
+2.00%
|
46.74
|
| Diluted NI Availto Com Stockholders |
|
-198.97
+16.94%
|
-239.56
+22.34%
|
-308.48
-143.30%
|
-126.79
|
| Depreciation Amortization Depletion Income Statement |
|
1.91
-9.48%
|
2.11
+2.88%
|
2.05
+73.67%
|
1.18
|
| Depreciation And Amortization In Income Statement |
|
1.91
-9.48%
|
2.11
+2.88%
|
2.05
+73.67%
|
1.18
|
| Depreciation Income Statement |
|
1.91
-9.48%
|
2.11
+2.88%
|
2.05
+73.67%
|
1.18
|
| Gain On Sale Of PPE |
|
6.00
|
0.00
|
0.00
|
—
|
| Rent And Landing Fees |
|
1.79
+31.89%
|
1.36
+50.89%
|
0.90
+9.76%
|
0.82
|
| Rent Expense Supplemental |
|
1.79
+31.89%
|
1.36
+50.89%
|
0.90
+9.76%
|
0.82
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
824.91
+48.22%
|
556.54
-33.08%
|
831.69
+17.98%
|
704.96
|
| Current Assets |
|
655.99
+68.08%
|
390.29
-40.13%
|
651.85
+36.72%
|
476.77
|
| Cash Cash Equivalents And Short Term Investments |
|
622.54
+69.39%
|
367.52
-40.52%
|
617.89
+75.12%
|
352.84
|
| Cash And Cash Equivalents |
|
80.24
-49.51%
|
158.93
-34.15%
|
241.36
+5.85%
|
228.01
|
| Other Short Term Investments |
|
542.30
+159.98%
|
208.59
-44.60%
|
376.53
+201.63%
|
124.83
|
| Receivables |
|
5.86
-0.31%
|
5.88
+40.26%
|
4.19
-95.90%
|
102.38
|
| Accounts Receivable |
|
5.86
-0.31%
|
5.88
+40.26%
|
4.19
-95.90%
|
102.38
|
| Inventory |
|
—
|
0.00
-100.00%
|
12.02
+73.66%
|
6.92
|
| Raw Materials |
|
—
|
0.00
-100.00%
|
7.16
+99.69%
|
3.58
|
| Work In Process |
|
—
|
0.00
-100.00%
|
4.11
+119.26%
|
1.87
|
| Finished Goods |
|
—
|
0.00
-100.00%
|
0.76
-48.29%
|
1.47
|
| Prepaid Assets |
|
20.51
+120.95%
|
9.28
-38.49%
|
15.09
+27.69%
|
11.82
|
| Other Current Assets |
|
7.08
-6.97%
|
7.61
+186.48%
|
2.65
-5.65%
|
2.81
|
| Total Non Current Assets |
|
168.92
+1.61%
|
166.25
-7.56%
|
179.84
-21.19%
|
228.19
|
| Net PPE |
|
26.32
-22.73%
|
34.07
-54.78%
|
75.34
-9.51%
|
83.26
|
| Gross PPE |
|
70.06
+6.59%
|
65.73
-49.83%
|
131.01
+2.85%
|
127.38
|
| Accumulated Depreciation |
|
-43.74
-38.16%
|
-31.66
+43.14%
|
-55.67
-26.17%
|
-44.13
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
4.36
+11.37%
|
3.91
-38.70%
|
6.38
+28.04%
|
4.99
|
| Construction In Progress |
|
—
|
0.00
-100.00%
|
5.67
+4.79%
|
5.41
|
| Other Properties |
|
37.52
+1.38%
|
37.01
-48.92%
|
72.45
+0.45%
|
72.12
|
| Leases |
|
28.19
+13.62%
|
24.81
-46.66%
|
46.51
+3.66%
|
44.87
|
| Goodwill And Other Intangible Assets |
|
98.14
+5.02%
|
93.46
+7.59%
|
86.86
+2.96%
|
84.36
|
| Goodwill |
|
25.36
+13.12%
|
22.41
-15.03%
|
26.38
+3.12%
|
25.58
|
| Other Intangible Assets |
|
72.79
+2.46%
|
71.04
+17.46%
|
60.48
+2.90%
|
58.78
|
| Investments And Advances |
|
30.24
+10.10%
|
27.46
+1160.39%
|
2.18
-94.55%
|
39.98
|
| Other Investments |
|
30.24
+10.10%
|
27.46
+1160.39%
|
2.18
|
—
|
| Non Current Deferred Assets |
|
8.65
-12.20%
|
9.86
-19.71%
|
12.28
-15.50%
|
14.53
|
| Non Current Deferred Taxes Assets |
|
8.65
-12.20%
|
9.86
-19.71%
|
12.28
-15.50%
|
14.53
|
| Other Non Current Assets |
|
5.56
+297.50%
|
1.40
-56.06%
|
3.18
-47.47%
|
6.06
|
| Total Liabilities Net Minority Interest |
|
626.01
+11.13%
|
563.29
-9.73%
|
624.02
+172.55%
|
228.96
|
| Current Liabilities |
|
62.92
+57.09%
|
40.05
-45.64%
|
73.67
-2.96%
|
75.92
|
| Payables And Accrued Expenses |
|
25.66
+48.02%
|
17.34
-10.73%
|
19.42
-20.26%
|
24.35
|
| Payables |
|
5.17
-28.46%
|
7.23
+9.73%
|
6.59
-40.04%
|
10.98
|
| Accounts Payable |
|
5.17
-28.46%
|
7.23
+9.73%
|
6.59
-40.04%
|
10.98
|
| Current Accrued Expenses |
|
20.49
+102.69%
|
10.11
-21.23%
|
12.83
-4.01%
|
13.37
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
9.94
-19.11%
|
12.29
-24.43%
|
16.26
-5.45%
|
17.20
|
| Current Debt And Capital Lease Obligation |
|
3.86
+7.25%
|
3.60
-56.84%
|
8.34
-0.45%
|
8.38
|
| Current Capital Lease Obligation |
|
3.86
+7.25%
|
3.60
-56.84%
|
8.34
-0.45%
|
8.38
|
| Current Deferred Liabilities |
|
—
|
—
|
—
|
—
|
| Current Deferred Revenue |
|
—
|
—
|
—
|
—
|
| Other Current Liabilities |
|
23.46
+243.63%
|
6.83
-76.98%
|
29.65
+14.11%
|
25.98
|
| Total Non Current Liabilities Net Minority Interest |
|
563.09
+7.62%
|
523.24
-4.93%
|
550.34
+259.62%
|
153.04
|
| Long Term Debt And Capital Lease Obligation |
|
59.53
-4.69%
|
62.46
-51.98%
|
130.06
-3.30%
|
134.51
|
| Long Term Debt |
|
49.70
-3.17%
|
51.32
-49.56%
|
101.75
-1.01%
|
102.79
|
| Long Term Capital Lease Obligation |
|
9.83
-11.71%
|
11.14
-60.67%
|
28.32
-10.73%
|
31.72
|
| Non Current Deferred Liabilities |
|
7.97
+13.12%
|
7.04
-6.63%
|
7.54
-8.65%
|
8.26
|
| Non Current Deferred Taxes Liabilities |
|
7.97
+13.12%
|
7.04
-6.63%
|
7.54
-8.65%
|
8.26
|
| Other Non Current Liabilities |
|
495.59
+9.23%
|
453.73
+9.93%
|
412.74
+3919.24%
|
10.27
|
| Stockholders Equity |
|
198.90
+3045.81%
|
-6.75
-103.25%
|
207.67
-56.37%
|
476.01
|
| Common Stock Equity |
|
198.90
+3045.81%
|
-6.75
-103.25%
|
207.67
-56.37%
|
476.01
|
| Capital Stock |
|
3.69
+25.23%
|
2.94
+2.15%
|
2.88
+1.59%
|
2.84
|
| Common Stock |
|
3.69
+25.23%
|
2.94
+2.15%
|
2.88
+1.59%
|
2.84
|
| Share Issued |
|
62.53
+27.64%
|
48.99
+2.41%
|
47.83
+1.84%
|
46.97
|
| Ordinary Shares Number |
|
62.53
+27.64%
|
48.99
+2.41%
|
47.83
+1.84%
|
46.97
|
| Additional Paid In Capital |
|
1,582.37
+34.89%
|
1,173.07
+2.12%
|
1,148.75
+3.18%
|
1,113.39
|
| Retained Earnings |
|
-1,328.94
-17.61%
|
-1,129.96
-26.90%
|
-890.41
-53.01%
|
-581.93
|
| Gains Losses Not Affecting Retained Earnings |
|
-58.22
-10.27%
|
-52.80
+1.41%
|
-53.55
+8.13%
|
-58.29
|
| Other Equity Adjustments |
|
-58.22
-10.27%
|
-52.80
+1.41%
|
-53.55
+8.13%
|
-58.29
|
| Total Equity Gross Minority Interest |
|
198.90
+3045.81%
|
-6.75
-103.25%
|
207.67
-56.37%
|
476.01
|
| Total Capitalization |
|
248.60
+457.75%
|
44.57
-85.59%
|
309.42
-46.54%
|
578.80
|
| Working Capital |
|
593.07
+69.33%
|
350.24
-39.42%
|
578.18
+44.24%
|
400.86
|
| Invested Capital |
|
248.60
+457.75%
|
44.57
-85.59%
|
309.42
-46.54%
|
578.80
|
| Total Debt |
|
63.39
-4.04%
|
66.06
-52.27%
|
138.41
-3.14%
|
142.89
|
| Capital Lease Obligations |
|
13.69
-7.08%
|
14.74
-59.80%
|
36.66
-8.58%
|
40.10
|
| Net Tangible Assets |
|
100.76
+200.55%
|
-100.21
-182.95%
|
120.81
-69.15%
|
391.65
|
| Tangible Book Value |
|
100.76
+200.55%
|
-100.21
-182.95%
|
120.81
-69.15%
|
391.65
|
| Held To Maturity Securities |
|
—
|
—
|
0.00
-100.00%
|
39.98
|
| Investmentin Financial Assets |
|
—
|
—
|
0.00
-100.00%
|
39.98
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-177.96
+2.61%
|
-182.73
-25.22%
|
-145.93
-0.60%
|
-145.06
|
| Cash Flow From Continuing Operating Activities |
|
-177.96
+2.61%
|
-182.73
-25.22%
|
-145.93
-0.60%
|
-145.06
|
| Net Income From Continuing Operations |
|
-198.97
+16.94%
|
-239.56
+22.34%
|
-308.48
-143.30%
|
-126.79
|
| Depreciation Amortization Depletion |
|
14.76
+16.76%
|
12.64
+6.23%
|
11.90
+39.39%
|
8.54
|
| Depreciation |
|
14.76
+16.76%
|
12.64
+6.23%
|
11.90
+39.39%
|
8.54
|
| Depreciation And Amortization |
|
14.76
+16.76%
|
12.64
+6.23%
|
11.90
+39.39%
|
8.54
|
| Other Non Cash Items |
|
39.66
+109.50%
|
18.93
-57.29%
|
44.32
+647.98%
|
5.92
|
| Stock Based Compensation |
|
17.68
-20.57%
|
22.26
-36.57%
|
35.09
+2.60%
|
34.20
|
| Deferred Tax |
|
1.59
-34.62%
|
2.43
+26.44%
|
1.92
+230.68%
|
-1.47
|
| Deferred Income Tax |
|
1.59
-34.62%
|
2.43
+26.44%
|
1.92
+230.68%
|
-1.47
|
| Operating Gains Losses |
|
-35.42
-329.80%
|
15.41
+798.78%
|
-2.21
+90.01%
|
-22.08
|
| Gain Loss On Investment Securities |
|
-12.40
|
—
|
—
|
—
|
| Net Foreign Currency Exchange Gain Loss |
|
-23.02
-249.33%
|
15.41
+798.78%
|
-2.21
+90.01%
|
-22.08
|
| Change In Working Capital |
|
-6.79
-72.16%
|
-3.94
-104.78%
|
82.44
+290.02%
|
-43.38
|
| Change In Receivables |
|
-8.60
-283.28%
|
-2.24
-102.27%
|
98.68
+301.04%
|
-49.08
|
| Changes In Account Receivables |
|
-8.60
-283.28%
|
-2.24
-69.54%
|
-1.32
+67.60%
|
-4.08
|
| Change In Inventory |
|
0.00
-100.00%
|
2.42
+135.92%
|
-6.74
+2.66%
|
-6.92
|
| Change In Payables And Accrued Expense |
|
1.81
+143.84%
|
-4.12
+56.60%
|
-9.50
-175.24%
|
12.62
|
| Change In Accrued Expense |
|
4.47
+179.30%
|
-5.64
-5.89%
|
-5.33
-257.40%
|
3.38
|
| Change In Payable |
|
-2.67
-275.46%
|
1.52
+136.46%
|
-4.17
-145.13%
|
9.24
|
| Change In Account Payable |
|
-2.67
-275.46%
|
1.52
+136.46%
|
-4.17
-145.13%
|
9.24
|
| Investing Cash Flow |
|
-321.62
-297.35%
|
162.97
+179.23%
|
-205.69
-12.56%
|
-182.73
|
| Cash Flow From Continuing Investing Activities |
|
-321.62
-297.35%
|
162.97
+179.23%
|
-205.69
-12.56%
|
-182.73
|
| Net PPE Purchase And Sale |
|
-0.44
+96.24%
|
-11.69
-63.39%
|
-7.15
+59.55%
|
-17.69
|
| Purchase Of PPE |
|
-0.44
+96.24%
|
-11.69
-63.39%
|
-7.15
+59.55%
|
-17.69
|
| Capital Expenditure |
|
-0.44
+96.24%
|
-11.69
-63.39%
|
-7.15
+59.55%
|
-17.69
|
| Net Investment Purchase And Sale |
|
-321.18
-283.89%
|
174.66
+187.97%
|
-198.53
-21.69%
|
-163.15
|
| Purchase Of Investment |
|
-658.38
-82.96%
|
-359.84
+1.80%
|
-366.44
-124.61%
|
-163.15
|
| Sale Of Investment |
|
337.19
-36.91%
|
534.50
+218.33%
|
167.91
|
0.00
|
| Net Business Purchase And Sale |
|
—
|
0.00
|
0.00
+100.00%
|
-1.90
|
| Purchase Of Business |
|
—
|
0.00
|
0.00
+100.00%
|
-1.90
|
| Net Intangibles Purchase And Sale |
|
—
|
—
|
—
|
0.00
|
| Purchase Of Intangibles |
|
—
|
—
|
—
|
0.00
|
| Financing Cash Flow |
|
415.40
+798.31%
|
-59.49
-116.40%
|
362.72
+25001.80%
|
1.45
|
| Cash Flow From Continuing Financing Activities |
|
415.40
+798.31%
|
-59.49
-116.40%
|
362.72
+25001.80%
|
1.45
|
| Net Issuance Payments Of Debt |
|
0.00
+100.00%
|
-53.05
|
0.00
|
0.00
|
| Issuance Of Debt |
|
—
|
—
|
0.00
|
0.00
|
| Repayment Of Debt |
|
0.00
+100.00%
|
-53.05
|
0.00
|
0.00
|
| Long Term Debt Issuance |
|
—
|
—
|
0.00
|
0.00
|
| Long Term Debt Payments |
|
0.00
+100.00%
|
-53.05
|
0.00
|
0.00
|
| Net Long Term Debt Issuance |
|
0.00
+100.00%
|
-53.05
|
0.00
|
0.00
|
| Net Common Stock Issuance |
|
391.90
+18359.68%
|
2.12
+589.29%
|
0.31
-78.69%
|
1.45
|
| Proceeds From Stock Option Exercised |
|
23.50
|
0.00
|
0.00
|
—
|
| Net Other Financing Charges |
|
—
|
-8.56
-102.36%
|
362.41
|
—
|
| Changes In Cash |
|
-84.18
-6.23%
|
-79.25
-813.54%
|
11.11
+103.40%
|
-326.35
|
| Effect Of Exchange Rate Changes |
|
5.66
+213.85%
|
-4.97
-319.38%
|
2.27
+223.70%
|
-1.83
|
| Beginning Cash Position |
|
160.33
-34.44%
|
244.54
+5.78%
|
231.17
-58.67%
|
559.35
|
| End Cash Position |
|
81.80
-48.98%
|
160.33
-34.44%
|
244.54
+5.78%
|
231.17
|
| Free Cash Flow |
|
-178.40
+8.24%
|
-194.42
-27.00%
|
-153.08
+5.94%
|
-162.75
|
| Interest Paid Supplemental Data |
|
25.07
+21.89%
|
20.57
+21.86%
|
16.88
+82.52%
|
9.25
|
| Amortization Of Securities |
|
-10.46
+4.02%
|
-10.90
+0.15%
|
-10.92
|
0.00
|
| Common Stock Issuance |
|
391.90
+18359.68%
|
2.12
+589.29%
|
0.31
-78.69%
|
1.45
|
| Issuance Of Capital Stock |
|
391.90
+18359.68%
|
2.12
+589.29%
|
0.31
-78.69%
|
1.45
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-03-09 View
- 42026-03-06 View
- 42026-03-06 View
- 42026-03-06 View
- 42026-03-06 View
- 42026-03-04 View
- 42026-03-04 View
- 42026-03-04 View
- 42026-03-04 View
- 10-K2026-03-02 View
- 8-K2026-03-02 View
- 42026-02-27 View
- 42026-02-27 View
- 42026-01-14 View
- 8-K2026-01-13 View
- 42026-01-12 View
- 8-K2026-01-09 View
- 8-K2025-12-04 View
- 42025-11-10 View
- 10-Q2025-11-10 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|